脾多肽注射液联合TACE治疗原发性肝癌及其对免疫功能的影响

Lienal polypeptide injection combined with transcatheter hepatic arterial chemoembolization for treating primary hepatic cancer: Curative effect and influence on cellular immune function

目的:探讨原发性肝癌患者应用脾多肽注射液联合经导管动脉化疗栓塞术(trascatheter arterial chemoembolization,TACE)治疗的疗效及其对细胞免疫功能的影响.方法:将60例原发性肝癌行TACE治疗的患者随机分为观察组30例和对照组30例,观察组在治疗同时加用脾多肽注射液.观察两组患者治疗后的全身状况、不良反应,并检测外周血T细胞亚群及天然杀伤(natural killer cell,NK)细胞变化.结果:术后两组肿瘤体积及甲胎蛋白(alpha fetoprotein,AFP)值均有所下降,但肿瘤缓解率及AFP值差异无统计学意义(P>0.05),观察组患者的平均KPS评分明显高于对照组,差异有统计学意义(80.7分±9.2分vs79.3分±8.4分,P<0.05),而不良反应发生率亦低于对照组(P<0.05).术后观察组CD3^+、CD4^+淋巴细胞百分率、CD4^+/CD8^+比值及N K细胞百分率均明显升高,CD8^+淋巴细胞百分率数量显著下降,与对照组术后比较差异有统计学意义(CD3^+:63.37%±8.38%vs 59.02%±8.41%,P<0.05;CD4^+:38.20%±5.60%vs 35.30%±5.80%,P<0.05;CD4^+/CD8^+:1.92±0.47 v s 1.57±0.23,P<0.01;N K:20.34%±5.46%v s 17.62%±3.10%;CD8^+:24.17%±4.05%vs 26.23%±4.26%,P<0.05).结论:在原发性肝癌TACE治疗过程中,应用脾多肽注射液能够有效改善患者的全身状况和细胞免疫功能.

AIM ： To evaluate the curative effect of lienal polypeptide injection combined with transcatheter hepatic arterial chemoembolization（TACE） in treating patients with primary hepatic cancer and the effect on cellular immune function. METHODS： Sixty patients with primary liver cancer who would receive TACE treatment were randomly divided into an observation group and a control group, with 30 cases in each group. The observation group was additionally given lienal polypeptide injection. The patients＇ condition, toxic and side effects, and changes in T cell subset and natural killer（NK） cells in the peripheral blood were compared between the two groups after treatment. RESULTS： After operation, tumor size and α-fetoprotein（AFP） value decreased in both groups, but the differences in the tumor remission rate and AFP value had no statistical significance（P 〈0.05）. Average KPS score was significantly higher in the observation group than in the control group（80.7 ± 9.2 vs 79.3 ± 8.4, P 〈0.05）, while the incidence of side effects was lower than that of the control group（P 〈0.05）. CD3~＋ and CD4~＋ lymphocyte percentages, CD4~＋/CD8~＋ ratio and NK cell percentage were significantly higher, and CD8~＋ lymphocyte percentage was significantly lower in the observation group than in the control group（CD3~＋： 63.37% ± 8.38% vs 59.02% ± 8.41%, P 〈0.05; CD4~＋： 38.20% ± 5.60% vs 35.30% ± 5.80%, P 〈0.05; CD4~＋/CD8~＋： 1.92 ± 0.47 vs 1.57 ± 0.23, P 〈0.01; NK： 20.34% ± 5.46% vs 17.62%± 3.10%, P 〈0.05; CD8~＋： 24.17% ± 4.05% vs 26.23% ± 4.26%, P 〈0.05.CONCLUSION： In primary liver cancer, the application of lienal polypeptide injection together with TACE treatment can effectively improve the patient＇s condition and immune function.